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Abstract
Without a scale‐down model for perfusion, high resource demand makes cell line
screening or process development challenging, therefore, potentially successful cell lines
or perfusion processes are unrealized and their ability untapped. We present here the
refunctioning of a high‐capacity microscale system that is typically used in fed‐batch
process development to allow perfusion operation utilizing in situ gravity settling and
automated sampling. In this low resource setting, which involved routine perturbations in
mixing, pH and dissolved oxygen concentrations, the specific productivity and the
maximum cell concentration were higher than 3.0 × 106mg/cell/day and 7 × 107 cells/ml,
respectively, across replicate microscale perfusion runs conducted at one vessel volume
exchange per day. A comparative analysis was conducted at bench scale with vessels
operated in perfusion mode utilizing a cell retention device. Neither specific productivity
nor product quality indicated by product aggregation (6%) was significantly different
across scales 19 days after inoculation, thus demonstrating this setup to be a suitable and
reliable platform for evaluating the performance of cell lines and the effect of process
parameters, relevant to perfusion mode of culturing.
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1 | INTRODUCTION
Since the approval of the first licensed monoclonal antibody (mAb) in
1986, the demand for mAbs as therapeutic agents has developed into
a multi‐billion dollar per year market (Liu, 2014). Process optimization
for large manufacturing facilities based on fed‐batch cell cultivation
allowed sufficient productivity of high product quality mAbs (Birch &
Racher, 2006). On the other hand, continuous bioprocessing employ-
ing perfusion bioreactors is utilized in the production of molecules that
proved to be challenging to express or recover. The low bioreactor
residence times associated with continuous production systems, and
the continuous removal of potentially toxic by‐products, allows cells to
reach high cell concentrations and improves total functional produc-
tion. Currently, continuous production is widely accepted as beneficial
for the manufacture of products such as infliximab (Remicade) that
exhibited particularly low titres (B. Kelley, 2009), and haemoglobin
factor VIII (ReFacto), which required minimal residence times in the
bioreactor (Vogel et al., 2012).
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As the demand for therapeutic mAb production increased, key
improvements were made in the areas of safety, efficacy, and quality
(Dimitrov, 2012), among which the utilization of scale down systems to
investigate process robustness played an important role (Kochanowski &
Malphettes, 2013). Automated single use microscale bioreactor systems
were evaluated as a model for large scale fed‐batch bioprocessing
systems (Hsu, Aulakh, Traul, & Yuk, 2012; Moses, Manahan, Ambrogelly,
& Ling, 2012; Nienow et al., 2013). Microscale bioreactors were reported
to shorten the timeline towards commercial production by allowing
multifactorial process optimization, in line with the current Quality by
Design guidelines (FDA, 2008). pH and dissolved oxygen (DO) could be
accurately controlled both in microscale and in large scale (Rameez,
Mostafa, Miller, & Shukla, 2014). Informing process control at large scale
involves an extensive understanding of the physical characteristics and
limitations of the system investigated at microscale (Nienow et al., 2013).
With the increasing interest in continuous bioprocessing, specific
industrial applications are now assessed on a case by case basis (Shukla,
Wolfe, Mostafa, & Norman, 2017), from an operational, environmental,
and economic stance (Pollock, Ho, & Farid, 2013). The consideration of
the option of a continuous process necessitates the comprehensive
process development and optimization be carried out within compatible
time scales and operational complexity to that established for fed‐batch
processes, whereby microscale systems prove vital (Birch & Racher,
2006). Commercial fed‐batch microscale system performance has been
reported to demonstrate sufficient scalability to bench scale (Hsu et al.,
2012). Microscale systems operated at continuous mode are yet to be
evaluated to ascertain the scalability of the operation with regard to
process parameters such as maximal cell concentration supported,
productivity and product quality attributes.
To achieve very high cell concentrations, perfusion processes require
a cell retention device. Such devices exploit physical properties, such as
cell size (filtration) or density (gravity settling or centrifugation) and have
been evaluated for their performance at increasing scales (Voisard,
Meuwly, Ruffieux, Baer, & Kadouri, 2003). Adaptation of existing fed‐
batch microscale cell culture systems to continuous cell culturing
applications is a relatively recent avenue for perfusion process
development. Due to the highly engineered nature of microscale systems,
it is difficult to repurpose them for perfusion by retrofitting a cell
retention device. Microtitre plate based systems such as SimCell platform
(Seahorse; Legmann et al., 2009) and BioLector Pro (m2p labs; Blesken,
Olfers, Grimm, & Frische, 2016) offer high experimental capacity. These
systems, however, would require significant operator interaction to mimic
perfusion through an adapted cell retention methodology. Alternative
small scale perfusion models for media development were also evaluated
(Du et al., 2015; Huang, Lin, & Yang, 2015); these, however, were not able
to measure and control process parameters in real time to allow
extensive bioprocess development activities to be conducted.
More recently, microscale systems have been developed that
were specifically designed to operate in perfusion mode (Mozdzierz
et al., 2015) but they have not yet been evaluated within the context
of mammalian expression systems and, as novel applications,
inherently will require significant economic and technical investment
from the end user point of view.
Gravity cell settling within the culture vessel was proposed as a
method that allows perfusion without the requirement to retrofit a
cell retention device. Earlier studies conducted using traditional
gravity settling devices (Searles, Todd, & Kompala, 1994) can
successfully be adopted in the design of a microscale cell settling
method. An early application using this strategy (Goletz, Stahn, &
Kreye, 2018) and several industrial investigations (BioMarin Phar-
maceutical, 2017; MilliporeSigma, 2017) highlighted an emerging
interest in adopting this method, although no specific reports exist on
a thorough comparative evaluation of this adapted system.
Here, the development and comparative evaluation of a micro-
scale bioreactor system operating under pseudo‐perfusion mode,
which utilizes gravity cell settling, is presented. The operational
capacity of microscale bioreactor systems (both the 24‐ and 48‐
vessel variants) and the functionality of the robotic liquid handling
arm are explored to design an effective perfusion mimic microscale
process. The transient effects of temporary interruption of agitation
and gas sparging on the culture vessels with regard to settling time is
investigated to assess the operational feasibility of this high‐capacity
system. The productivity of a mammalian cell line expressing a mAb,
and the product quality under operation in microscale perfusion
mode are compared to their cognate values in the commonly used
bench top perfusion reactor operating on alternating tangential flow
(ATF) with hollow fibre filter for cell retention.
2 | MATERIALS AND METHODS
2.1 | Growth environment and cultivation
conditions
A Chinese hamster ovary (CHO) cell line expressing a high
concentration of bispecific mAb was used in this study. Two animal
component free proprietary media compositions were used; one
developed specifically for passaging cultures (basal), and another
developed for supporting high cell concentrations associated with
perfusion systems (enriched). The cells were revived from a frozen cell
stock and sub‐cultured twice weekly in vented shake flasks (Corning,
Corning, NY) containing basal medium in a humidified orbital shaker
incubator maintained at 37°C with ambient 5% CO2 content.
2.2 | Microscale and bench top perfusion process
operation regimes
In Experiment 1, two 7 L stirred‐tank reactor (STR) bench scale
(Chemglass, Vineland, NJ) vessels and 24 15‐ml microscale bioreactors
(ambr 15; Sartorious, Gottingen, Germany) were inoculated from the
same source, and cells were cultured in basal media, with a starting
volume of 3.5 and 15ml, respectively. Upon the initiation of perfusion,
the working volumes are adjusted to 3 and 10.7ml for bench scale and
microscale vessels, respectively. The two bench scale vessels were
operated at 1.0 vessel volume exchange per day (VVD). Microscale
bioreactors were operated at 1.0VVD or 1.5 VVD. The data presented
are solely derived from cultures operated at 1.0 VVD to allow
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comparability across scales. In Experiment 2, 12 microscale bioreactors
(ambr 15) were inoculated with cells in the basal media for parallel
operation and from the same inoculum train, with a starting volume of
15ml. These vessels were also operated at 1.0 VVD.
Microscale reactors operated at 1.0 VVD were allowed three
partial media exchange steps per day, conducted at 8‐hr intervals.
Microscale vessels operated at 1.5 VVD were allowed 4.5 partial
media exchanges per day on average; four and five exchanges on
consecutive days, conducted at 5‐hr intervals, with one 8‐hr interval
included on the days with four exchanges, aligning with routine
sampling of 1.0 VVD culture stations. All cultivations were perfused
with enriched media starting from the initiation of perfusion mode,
approximately 96 hr after inoculation.
Gravity cell settling was used to introduce cell retention and
exchange of cell‐free culture media to facilitate the pseudo‐perfusion
mode of operation in the microscale bioreactors. The bench scale
vessels were operated in perfusion mode using an ATF device
(Repligen, Waltham, MA) in combination with 0.22 μm hollow fibre
filter for cell retention, and continuous perfusion rate of 1.0 VVD. pH
and DO were monitored online in the two 7‐L STRs via probes
(Mettler Toledo, Columbus, OH), and in the microscale vessels via
fluorescent spot sensors (Presens, Regensburg, Germany) located on
the bottom surface. pH (7.2) and DO (50%) control was maintained
through CO2 and O2 sparging, respectively. Agitation was increased
with increasing oxygen demand, and antifoam was added as required.
2.3 | Microscale cell retention – liquid
exchange step
Vessels (V) were arranged in positions 1–6 on each culture station
(CS). Gravity cell settling was achieved by stopping gassing and
agitation, allowing cells to settle in preparation for liquid exchange.
Following an initial investigation (Section 3.1.1), a settling time of
30min was allowed in all CSs in Experiment 1. Experiment 2
evaluated settling times of 33.5 and 37min in two CSs.
Liquid was removed from the vessels in batches of <0.9 ml and
the pipette tip was only minimally immersed to avoid affecting the
settling of the cells. This was facilitated by tuning the software of the
automated microscale system, which allowed fine control over
the height at which the liquid removal pipette travels into the vessel
(to the precision of 0.01mm). The tip height was plotted against the
vessel volume by weighing the remaining liquid after aspirating at
different recorded heights and the depth from which the pipette
sampled was determined from this plot (slope = 0.3899; y‐intercept =
0.6203, R² = 0.9987). The sequential exchange of liquid automated
by the microscale controller, took 20–30min of additional time
before cells were resuspended and gassing was reinitiated.
2.4 | Bioreactor sampling and sample analysis
All vessels were sampled daily. Viable cell counts and percentage
viability (via the trypan blue exclusion method) were conducted using
an automated Vi‐Cell XR cell counter (Beckman Coulter, Brea, CA).
Offline metabolite analysis for glucose and lactate concentration of
the samples collected from the microscale vessels and the STR
vessels were carried out in YSI 2900 (Xylem Analytics, Letchworth
Garden City, UK) and Bioprofile FLEX (Nova Biomedical, Waltham,
MA), respectively. The amino acid content of the spent medium was
determined by liquid chromatography (ACQUITY UPLC system, Ac-
cQTag Ultra C18 column; Waters), and the peaks were evaluated
against commercial standards (Waters, Milford, MA). All values were
scaled to maintain commercial confidentiality. The mAb concentra-
tion was determined using Protein A’dip‐and‐read’ Biosensors on the
Octet System (Pall ForteBio, Fremont, CA). A serial dilution of the
purified mAb product was performed and run in parallel with inter
assay controls to determine the titre and control run variation. mAb
aggregation was determined by SEC‐UPLC. Unpurified, clarified cell
culture supernatant was filtered through a 0.22‐μm AcroPrep plate
filter (Pall, New York, NY) before loading the supernatant to the
automated injection by UPLC (Waters) on SEC column (Acquity
UPLC Protein BEH SEC. 200Å; Waters); peak detections were made
at wavelengths 220 and 280 nm. Protein A capture purification was
performed on pooled perfusate material from each experiment
(microscale 1, 2A, 2B, and bench scale) and aggregate abundance was
determined by SEC‐UPLC as detailed above.
2.5 | Rate calculations
Integral viable cell concentration, specific glucose consumption, and
specific net lactate change is calculated as reported elsewhere (Adams,
Korke, & Hu, 2007; Villiger‐Oberbek, Yang, Zhou, & Yang, 2015).
The integral viable cell concentration (IVCC) for each culture is
calculated by:
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No product retention occurred and thus specific productivity (qp,n)
was calculated by:
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2.6 | Data analysis
Mean and standard deviation (SD) are reported as (mean ± SD) for all
replicate data. The number of replicates from a single culture station
in Experiments 1, 2A, and 2B microscale setup were n = 6, 4, and 6,
respectively. Paired or unpaired two tailed t tests were used, where
appropriate, to determine significance across conditions and each
specific application is referred in the text. Comparison from
microscale to bench scale (n = 2) was made using one‐way analysis
of variance. Vessels within a single culture station were treated as
replicates for reporting statistical significance except when the vessel
position effect was investigated. All raw data are provided for
reference (Supporting Information Data).
3 | RESULTS AND DISCUSSION
3.1 | Process design and evaluation
3.1.1 | Settling time requirements
The settling time for the microscale cell retention was determined
keeping the following design considerations in mind: (a) allowing the
exchange of an almost cell‐free fraction, i.e. the perfusate, with fresh
medium, (b) maximizing potential total volume exchanged per day,
while minimizing the volume exchanged per cell settling to mimic the
operation at larger scales, and (c) allowing an operation at industrially
relevant dilution rates, whilst minimizing the effects the periodic cell
settling and media exchanges.
The limiting factor in determining the number of cell settling steps in
the current design was the capacity of the automated sampling station
and operator requirements. Minimal operator intervention (mainte-
nance carried only once per day) was achieved by liquid exchange using
1‐ml capacity pipette tips adjusted for use at 90% of their capacity and
this was repeated three times in each exchange step. The depth at
which the pipette tip was immersed to disturb the settled cells
minimally was 2.3mm below the liquid surface.
With a simplified microscale vessel geometry by a rectangular prism
(Figure 1a; 18mmx31mmx63mm; Nienow et al., 2013), and
theoretical settling velocity of 1.4 cm/h for CHO cells (Searles et al.,
1994), the cells were calculated to travel 7mm in 30min during settling,
allowing the sampling of the top 2.7ml from the vessels. This nominally
“cell‐free” supernatant was investigated further, and 99% cell retention
was achieved after 30min (Figure 1c). To preserve the concept of
perfusion mimic and to avoid evaluation of a chemostat‐like environ-
ment, settling times <30min were avoided due to low efficiency cell
retention. The cells were challenged further by increasing the settling
time of the CSs to 33.5 and 37min, to comprehensively explore the
effect of extended exposure of the cells to micro‐aerated and nutrient‐
limited conditions on their viability (Section 3.2).
3.1.2 | Capacity
At 1.0 VVD and 1/3rd of the culture volume exchanged at each step,
a CS operating at 50% capacity (6 vessels out of a possible 12)
required additional 30min to handle the robotic liquid exchange.
Operating four CSs at 50% capacity required settling or sampling to
be scheduled for 12 hr per day and at‐line measurements such as
automated cell counting carried out required an additional 4 hr. The
necessary daily downtime for system maintenance, when the robotic
liquid handling arm was idle, was 30min. This setup allowed us to run
24 vessels in the 48‐vessel variant of the microscale system, which
would be sufficient for Design of Experiments (DoE) studies of
continuous systems.
Increasing the volume exchange rate to a higher value than
1.0 VVD would limit the physical space that the cells were to settle
into, thus the number of iterations of liquid exchange steps per day
would need to be increased. Although the capacity of this setup was
able to sustain operation at as high a volume exchange rate as
1.5 VVD, the corresponding specific growth rate (μ) of 0.062 hr−1
exceeded the maximum specific growth rate (μmax = 0.05 hr
−1)
reported for CHO cells (López‐Meza et al., 2016). Thus, this setup
was suitable for the range of all reported specific growth rates, at
which CHO cells could operate.
3.1.3 | Resuspension of the culture and recovery to
the set points
Gas sparging and agitation needed to be turned off to allow gravity
cell settling, and consequently, the measurements of pH and DO
were observed to rapidly decline during this period (Figure 2a1‐c). pH
dropped by approximately 0.8 units over 30min and the decline in
pH started immediately after the agitation was stopped, gradually
slowing down towards the end of the settling time. The DO
immediately and very sharply declined from the set point (50%)
down to below 5% saturation within 10min and readings plateaued
between 2 and 5% saturation. The pH and DO measurements
recovered following resuspension. The drop in DO and pH was likely
to be caused by the metabolic activity of the cells consuming residual
oxygen and producing CO2 and lactate. As oxygen became limited
(approximately after 10min of cell settling; Figure 2a2), the slowing
down of the cellular metabolic activity through reduced oxidative
phosphorylation at low (<5%) DO saturations (Heidemann, Lütke-
meyer, Büntemeyer, & Lehmann, 1998) could consequently have
slowed down the rate of pH drop, since CO2 production would
slow down.
The location of the optical sensors at the bottom of the vessel
was thought to contribute to the magnitude of these observed
changes (Figure 1). As cells settled down at the bottom of the vessel,
the sensors only picked up the parameters associated with an oxygen
depleted and by‐product accumulated local environment, which was
extremely hypoxic, but not representative of the entire culture.
Hydrodynamic investigation of the mixing time within microscale
vessels indicated that <5 s would be required for resuspension
(Nienow et al., 2013). pH was observed to recover back to its set
point immediately following resuspension, with initially a slight
increase above the set point for a very short period of time. The DO
rapidly responded to the reintroduction of aeration and agitation,
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however, the values were observed to overshoot immediately after
resuspension, only to recover to the set points within the first hour.
Increased sparging of oxygen into the vessel to recover the DO back
to 50% was thought to remove CO2 from the culture, resulting in the
slight elevation of the pH, an issue commonly mitigated in scale up
applications (Matsunaga, Kano, Maki, & Dobashi, 2009).
3.2 | Evaluation of the culture performance at
microscale
3.2.1 | Viable cell concentration
Microscale vessels reached the maximum viable cell concentration of
7.20 ± 1.14 × 107 cells/ml, 20 days after inoculation, whereas bench
scale cultures inoculated from the same source reached the maximum
viable cell concentration 13 days after inoculation and the maximum
viable cell concentration was 8.32 ± 0.55 × 107 cells/ml (Figure 2c). The
difference in maximum viable cell concentrations of the cultures was
not significant (p = 0.24). The exponential growth phase of the cultures
growing at microscale was longer than those growing at the bench
scale, and this was thought to be at least partially related to the
efficiency of gravity cell settling. At microscale, the percentage of
culture retained during each liquid exchange step dropped towards
95% as the cell concentration increased (Figure 2d). This minimal loss
was thought to be similar to a small and frequent cell bleed that could
have contributed to the depressed growth rates and lag time in
reaching maximum cell concentration. In contrast, cells were
considered to be retained at 100% efficiency (with no bleeding) at
the bench scale as the hollow fibre filter pore size was sufficiently
small to prevent the passage of cells.
Increasing the settling time from 30 to 33.5 min did not yield a
significant change (p = 0.91) in the maximum viable cell concentra-
tion, although the average maximum value attained was slightly
lower, 6.88 ± 2.13 × 107 cells/ml. Further increase in retention time
to 37min did not yield a significant change (p = 0.38 and 0.45,
F IGURE 1 Effect of settling time and culture cell concentration on the retention of cells, and the resulting pH and dissolved oxygen (DO)
effect. (a) Diagrammatic representation of microscale vessel dimensions detailing the location of optical sensors on the internal base of the
vessel. Measurements for vessel geometry taken from Nienow et al (2013). (b) Photograph of two microscale vessels populated with Chinese
hamster ovary cell cultures of concentrations of 2 × 107 cells/ml (on the left) and 1 × 108 cells/ml (on the right). The top image (B1) displays a
homogenous culture at the initiation of gravity settling whilst the bottom one (B2) displays the same vessels after 30min of settling. A sediment
layer and a cleared fraction are visible in the vessels settled for 30min indicated by the dashed box. (c) Percentage cell loss from microscale
reactor vessel following cell retention by incrementally increasing the gravity settling time from 15 to 30min, with starting concentration of
6.08 × 106 cells/ml across replicates. Data show mean ± SD, n = 6 [Color figure can be viewed at wileyonlinelibrary.com]
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respectively) in maximum viable cell concentration either, although
the average concentration was lower than that for 30 and 33.5 min,
6.53 ± 1.40 × 107 cells/ml. There was a variation in the time taken to
reach maximum viable cell concentration in Experiment 2A, with the
average 19.5 ± 1.73 days being slightly earlier than the 20 days after
inoculation observed for all replicates in Experiment 1. However, this
difference was not significant either (p = 0.49). Vessels across
Experiment 2B did not reach this maximal cell concentration until
much later (Day 25), and this difference was highly significant
(p < 0.001).
A nonsignificant decrease (p = 0.15) was observed in cell viability
(Figure 2b) on the day of the maximum viable cell concentration as
the settling time was increased from 30min (90.2 ± 2.0%) to 33.5 min
(86.9 ± 4.5%). The decrease in cell viability was not significant
(p = 0.18) when the settling time was further increased from
33.5min (86.9 ± 4.5%) to 37min (81.7 ± 6.1%). However, the total
F IGURE 2 The response of the microscale system process pH and DO to cell settling, and the subsequent impact on cell growth and viability
compared with bench scale operation. (a1) Sample traces from one microscale vessel in Experiment 1; inline DO (red) and pH (blue)
measurements recorded during the process. Both parameters are plotted on their respective axes against the process duration (days). Variation
in the acidity and oxygenation during one day of cultivation, which entails three exchange steps (1.0 VVD volume exchange rate), displayed the
recovery between liquid exchange steps back to control set points. (a2) Zoomed view to one settling period from (a1) representing system
response to cell settling and resuspension. (b) Viability (%) plotted against duration of cultivation (days) for the microscale vessels and the two
bench scale reactors. (c) Viable cell concentration (cells/ml) plotted against process duration (days) for the microscale vessels and the two bench
scale reactors. (d) Cell loss per liquid exchange step (%) determined as the ratio of the total cell content of perfusate to the total cell count for its
respective culture suspended plotted against culture age. For (b)–(d): Microscale reactors: (▲) Experiment 1, n = 6 (30min settling); (▼)
Experiment 2, n = 4 (33.5min settling); (■) Experiment 2, n = 6 (37min settling); Bench scale reactors: (♦) Experiment 1, n = 2. Data show
mean ± SD. (e) Average cell diameter (μm) plotted against process duration (days) for the cell samples in the microscale cultures (●) and in the
perfusate (○). Plot represents the mean for all microscale samples (n = 16) with SD shown when the variation was greater than 3.5% of the
mean. Perfusion initiation is indicated in each respective plot with an intersecting blue arrow. DO: dissolved oxygen [Color figure can be viewed
at wileyonlinelibrary.com]
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decrease in viability observed with increasing the settling time from
30min to 37min was statistically significant (p < 0.01), suggesting an
overall adverse effect of increasing the culture settling time on
viability.
3.2.2 | Culture retention and perfusate analysis
Cell content of the perfusate was determined to evaluate the
retention performance of the microscale experiments (Figure 2d).
F IGURE 3 Culture response in online and offline measured process parameters to the mode and the duration of cell retention. Online microscale
vessel readings have been averaged over their respective 24‐hr periods to provide a representative value for the day. All parameters are plotted
against process duration (days). (a) DO (%), online (b) pH, online (c) Glucose (g/L), offline (d) Lactate (g/L), offline (e) Specific glucose consumption rate
(g/cell/day), (f) Specific net lactate change (g/cell/day), (g) Titre (mg/L), offline (h) Specific productivity (mg/cell/day). For (a)–(h): Microscale reactors:
(▲) Experiment 1, n = 6 (30min settling); (▼) Experiment 2, n = 4 (33.5min settling); (■) Experiment 2, n =6 (37min settling); (○) combined
microscale from Experiment 1 and 2, n = 16; (♦) Bench scale reactors: Experiment 1, n = 2. Data show mean ± SD. Perfusion initiation is indicated in
each respective plot with an intersecting blue arrow. DO: dissolved oxygen [Color figure can be viewed at wileyonlinelibrary.com]
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Average cell retention on the day of maximum viable cell concentra-
tion was 96.2 ± 0.5, 97.5 ± 0.5, and 97.0 ± 1.8%, for Experiments 1,
2A, and 2B, respectively. These values were higher than the values
reported earlier (90% retention; MilliporeSigma, 2017) indicating
improved performance in the present setup.
As cultures progressed into the late exponential growth phase (18–
21 days after inoculation), Experiment 2 cultures with extended settling
times displayed a statistically significant increase in average cell
retention (p < 0.05). No significant difference was observed between
the two CSs with 33.5 and 37min retention times in Experiment 2.
The average diameter of the cells across all microscale culture
samples and microscale perfusate samples was 13.27 ± 0.95 and
9.50 ± 0.50 μm, respectively (n = 16; across 4 days [18–21]). The
difference between these measurements was highly significant
(p < 0.001; Figure 2e).
Viability of the perfusate samples at maximum viable cell
concentration (93.1 ± 4.8%) was consistently higher than that of the
homogenous microscale cultures (86.2 ± 5.5%; n = 16, p < 0.001).
Although cell viability was reported to affect settling velocity in early
reports (Searles et al., 1994), with nonviable cells moving 30–50%
slower than viable cells (Wang & Belovich, 2010), this was not observed
in the cultures investigated here. However, given the difference in size,
the cells removed were more likely those, which displayed lower
specific productivity due to their stage in cell cycle, as reported earlier
(Lloyd, Holmes, Jackson, Emery, & Al‐Rubeai, 2000).
3.2.3 | Variability within and across culture
stations, and across inoculum trains
The microscale vessels were serviced sequentially by the robotic arm
during perfusate‐fresh medium replacement, and this introduced
additional lag time for each vessel placed at positions 2–6 on each CS
(Figure S1C).
Viable cell concentrations were compared across positions to
identify any position‐specific variation in settling time across and
within CSs (Figure S1). Experiments 1 and 2A were evaluated as
biological replicates, and Experiments 2A and 2B as technical
replicates. There was no clear trend displaying significant differences
in both biological replicates, although some significant positional
effects were observed between the neighboring vessels in each CS
(Figure S1A,B). Increasing the settling time to 37min caused significant
variability across subsequently serviced vessels (Figure S1B). In line
with these observations, the suggested total settling and servicing
time of each vessel needed to be shorter than 41min for this cell line.
Although this observation will be cell line specific, the range of
operation investigated in this study provides a sufficiently wide
investigation space to select to operations range from.
3.2.4 | Controlled process parameters and
biochemical analysis
The microscale system was able to supply sufficiently large
volumes of oxygen to support the culture growth even at the high
viable cell concentrations observed, as was the case for the bench
scale system ( Figure 3a). The pH of both microscale and bench
scale cultures got slightly more acidic but were maintained within
the control set points for 7–10 days after inoculation (Figure 3b).
The culture pH further became more acidic from this day onward.
The bench scale systems recovered back to the initial set point,
whereas the pH of the microscale vessels consistently remained
slightly more acidic at 6.9.
Glucose was gradually consumed by the cultures before perfusion
being initiated at 4 days after inoculation (Figure 3c). Once perfusion
was initiated, the influx of enriched media increased culture glucose
concentrations, and glucose was increasingly utilized as viable cell
concentrations increased. Glucose was available for all cultures in
microscale vessels on the day of maximum viable cell concentration;
2.22 ± 0.37, 3.07 ± 1.02, and 3.98 ± 1.33 g/L, respectively, for Experi-
ments 1, 2A, and 2B, indicating that the cultures were not glucose‐
limited. The lactate accumulated during the batch phase of the
microscale cultures was 0.67 ± 0.05, 2.59 ± 0.48, and 3.12 ± 0.20 g/L
for Experiments 1, 2A, and 2B, respectively (Figure 3d). The lactate
concentration remained similar throughout the perfusion phase.
In contrast, glucose was fully utilized in the bench scale cultures,
with the remaining glucose determined as 0.51 ± 0.04 g/L on the day of
maximum viable cell concentration. The glucose concentration dropped
from a peak at the 6th day after inoculation (8.22 ± 0.25 g/L), and
was fully utilized starting from the 10th day after inoculation
(0.29 ± 0.01 g/L). A metabolic shift was observed as the cultures also
metabolized the available lactate, dropping from 1.70 ± 0.23 g/L on the
9th day after inoculation, to 0.04 ± 0.06 g/L by the 11th day after
inoculation. Utilization of lactate increased the pH, recovering the pH
back to the initial set point in these cultures. This metabolic switch did
not occur in any of the microscale vessels and consequently, the pH
continued to drop as discussed above.
A significant difference (p < 0.05) was observed in the glycine,
alanine, glutamine, and glutamate pools between the bench scale and
microscale cultures starting from the 12th day after inoculation. The
depletion of glucose to 0.29 ± 0.14 g/L on the 10th day following
inoculation was coupled with the utilization of lactate for pyruvate
production, which would then proceed into the citric acid (TCA) cycle
for the generation of energy. Pyruvate would selectively be
converted into α‐ketoglutarate, which enters the TCA cycle, and
excess pyruvate would be converted into glycine (Figure S2C). The
concurrent increase in the by‐product alanine concentration pro-
vided further support for the activation of this pathway (Figure S2B).
Glutamine concentration was shown to decrease (Figure S2A)
indicating that the glutamate pool was utilized in α‐ketoglutarate
production, rather than glutamine.
On the other hand, asparagine, cysteine, and serine were shown
to concurrently deplete over time for both bench scale and
microscale cultures (Figure S2D–F). The concentration of the other
amino acids remained constant, with slight statistically insignificant
variations (p > 0.05; Figures S3 and S4).
Despite these differences, the specific glucose consumption and
net specific lactate production (difference between production and
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back‐metabolization) of the microscale and bench scale systems were
similar (Figure 3e–f). Earlier reports indicated that even a small
variation in pH as 0.1 could significantly impact culture growth and
metabolism, in particular glucose consumption and lactate produc-
tion (Li, Vijayasankaran, Shen, Kiss, & Amanullah, 2010). The cell line
used in this study was very robust, withstanding a pH variation of 0.3
without demonstrating any observable differences in two major
indicators of metabolic activity after the 10th day following
inoculation. For sensitive cell lines, the variation in pH can be
confined to as small a range as needed by implementing two‐point
control in the microscale system.
3.2.5 | Productivity and product quality
On the day of the maximum viable cell concentration, the product
concentration was 189 ± 19, 267 ± 18, and 267 ± 13mg/L for micro-
scale Experiments 1, 2A, and 2B, respectively (Figure 3g). The
differences observed between Experiments 1 and 2A, as well as
between Experiments 1 and 2B, were significant (p < 0.001 for both).
The product concentration in the bench scale vessels was
253 ± 9mg/L at the point of maximum viable cell concentration and
the difference between the microscale and the bench scale product
concentration was not significant (p = 0.92).
The variation in cell‐specific productivity across cultures was
observed to decrease as the cultures approached similar phases
of operation (Figure 3h). The cultures were more uniform with
less variation towards the end of the process as implicated by
their average specific productivity (3.05 ± 1.1 × 106 mg/cell/day
on the 8th day after inoculation vs. 3.06 ± 0.17 × 106 mg/cell/day
on the 19th day after inoculation, p = 0.86). This indicated that
microscale perfusion was a robust mode of operation for
assessing productivity.
Protein A‐purified perfusate samples collected from the vessels
at the time of maximum viable cell concentration were assessed for
the purity of the monomer mAb for all operations. The product purity
achieved by cultivation at microscale was 93.3, 95.1, and 94.0% for
Experiments 1, 2A and 2B, respectively, and that achieved at bench
scale was 94.0%, indicating comparability across different scales of
operation.
Furthermore, the average monomer content of the perfusate was
also determined before Protein A purification. This “raw” quality
measurement indicated by the monomer content was 61.0 ± 0.7,
54.6 ± 8.7, and 53.3 ± 6.5%, for the microscale Experiments 1, 2A, and
2B, respectively. The differences observed between Experiments 1
and 2A and between Experiments 2A and 2B were not statistically
significant (p = 0.1 and 0.8, respectively). However, the product
quality was significantly lower in Experiment 2B than in Experiment 1
(p < 0.05). The long settling times could have caused reduced product
quality. Nevertheless, these measurements were all higher than the
monomer content of the bench scale cultures on the 14th day after
inoculation (44.8 ± 0.7%), and this difference between the bench
scale and microscale cultures was highly significant (p < 0.001,
compared to Experiment 1). Despite the variation observed in
Experiment 2, a settling time longer than 40min was still well‐
tolerated by this cell line, high quality product could still be achieved.
The microscale perfusion mimicking setup did not negatively impact
product quality as ATF bench scale perfusion environments were
reported to do so (W. Kelly et al., 2014; Walther, McLarty, &
Johnson, 2019).
These analyses were extended to evaluate the performance of
two additional cell lines grown in microscale perfusion as detailed in
this study and also to compare this with their performance in bench
scale reactors operating at their cell‐specific perfusion rate. No
significant difference was observed in specific productivity (p = 0.88)
or culture performance between the microscale and bench scale
modes of operation, providing additional support for the broad
applicability of the approach.
4 | CONCLUSIONS
In this study, the design and performance of a microscale
bioreactor system operating under pseudo‐perfusion mode was
explored, with several considerations outlined (Figure S5). Gravity
settling was used to facilitate cell retention, and a settling period
longer than 30 min was required for effective cell retention, where
95% of the cells were settled before liquid exchange, and that the
upper limit for cell settling period should be closer to, but shorter
than, 41 min to maintain viability above 86% for prolonged
cultivation periods.
The microscale system supported statistically comparable max-
imum cell concentration displayed in bench scale operation specific
for this experimental cell line, with cultures reaching very high cell
concentrations exceeding 7.0 × 107 cells/ml without being challenged
by oxygen limitation or increased acidity of the culture environment.
The slight differences in culture pH between the microscale and
bench scale operations did not yield differences in the CHO cell
physiology, with the specific glucose consumption and net specific
lactate production rates remaining similar.
The present setup could utilize either the 48‐ or the 24‐vessel
variants of the microscale system at 50% capacity with half of each
culture station being utilized at a time. At a liquid exchange rate of
one vessel volume per day, this setup allowed suitable main-
tenance downtime and a single operator intervention per day. Our
evaluation has shown the potential and applicability of this setup
in conducting multifactorial DoE to effectively evaluate perfusion
process set points, media optimization or as a cell line screen-
ing tool.
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